Skip to main content

Table 1 Subject group characteristics

From: Predominantly defective CD8+ T cell immunity to SARS-CoV-2 mRNA vaccination in lung transplant recipients

Group

Number

Mean age yrs (SD)

Female/male

Lungs transplanted double/single

On sirolimus

On tacrolimus

On prednisone

On MMF

On azathioprine

Initial vaccine mRNA-1273/BNT162b2

Booster vaccine mRNA-1273/BNT162b2

Mean years from TX to first VAC

Mean years from TX to COVID-19

Mean days from VAC to test (SD)

Mean days from boost to test (SD)

Mean days from COVID onset to test (SD)

A

Transplant vaccinated (unboosted)

21

61.8 (10.6)

10/11

11/10

5 (24%)

20 (95%)

21 (100%)

13 (62%)

2 (10%)

21/0

N/A

4.5 (3.2)

N/A

99.4 (43.8)

N/A

N/A

B

Transplant boosted (3rd dose)

19

64.5 (9.5)

8/11

8/11

4 (21%)

19 (100%)

19 (100%

11 (58%)

2 (11%)

19/0

18/1

4.6 (3.2)

N/A

189.4 (21.5)

17.1 (10.9)

N/A

C

Transplant covid-19*

8

58.9 (12.9)

3/5

5/3

0 (0%)

8 (100%)

8 (100%)

8 (100%)

0 (0%)

8/0**

4/0***

2.2 (1.1)

2.4 (1.1)

165.6 (85.4)

53.0 (28.4)**

134.4 (147.2)

D

Healthy controls vaccinated (unboosted)

21

51.9 (10.6)

15/6

N/A

N/A

N/A

N/A

N/A

N/A

6/16

N/A

N/A

N/A

121.0 (50.4)

N/A

N/A

Statistical comparisons

               

A vs D

0.0037

0.2082

      

 < 0.0001

   

0.1417

  

B vs D

0.0003

0.1086

          

 < 0.0001****

 

A vs B

0.4017

0.7605

0.5450

1.0000

1.0000

1.0000

1.0000

1.0000

  

0.9719

 

 < 0.0001****

 
  1. General characteristics are compared between groups of lung transplantation subjects and healthy control subjects. Relevant statistical analyses for differences (p values by Student’s t-test or Fisher’s exact test as appropriate) are given for comparisons between the groups. The post-COVID-19 group was not included in statistical comparisons due to its small number
  2. *3/8 were tested after COVID-19 occurred after vaccination with a third booster dose, 2/8 were tested after vaccination (no boost) after recovery from COVID-19, 2/8 were tested after COVID-19 occurred after vaccination (no boost), 1/8 was tested after vaccination and a third booster vaccination after COVID-19
  3. **All eight persons were vaccinated either before or after COVID-19
  4. ***Includes only the four persons who received a booster vaccination at some time before testing
  5. ****Comparison of days from most recent vaccination (either primary vaccination or third booster vaccination)
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us